MEIRAGTX HOLDINGS PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.93 USD | -1.20% |
|
-6.91% | -29.91% |
| 15/05 | Transcript : MeiraGTx Holdings plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM | |
| 09/05 | Earnings Flash (MGTX) MEIRAGTX Reports Q1 Revenue $697,000 | MT |
| Sales 2024 * | 49.77M 4.15B | Sales 2025 * | 273M 22.77B | Capitalization | 321M 26.77B |
|---|---|---|---|---|---|
| Net income 2024 * | -108M -9.01B | Net income 2025 * | 116M 9.68B | EV / Sales 2024 * | 6.45 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.18 x |
| P/E ratio 2024 * |
-3.22
x | P/E ratio 2025 * |
4.37
x | Employees | 402 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on MeiraGTx Holdings plc
More recommendations
More press releases
| 1 day | -1.00% | ||
| 1 week | -6.91% | ||
| Current month | +0.82% | ||
| 1 month | -1.40% | ||
| 3 months | -20.39% | ||
| 6 months | -8.55% | ||
| Current year | -29.91% |
1 week
4.92
5.39
1 month
4.925.93
Current year
4.687.57
1 year
3.498.35
3 years
3.4924.89
5 years
3.4930.23
10 years
3.4930.23
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Giroux
FOU | Founder | 61 | 20/15/20 |
| Chief Executive Officer | 59 | 20/15/20 | |
Robert Zeldin
CTO | Chief Tech/Sci/R&D Officer | 61 | 05/20/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 25/22/25 |
Thomas Shenk
BRD | Director/Board Member | 77 | 01/15/01 |
Keith Harris
CHM | Chairman | 71 | 01/15/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +9.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 4.92 | -1.40% | 24 341 |
| 30/24/30 | 4.99 | -0.20% | 161,253 |
| 29/24/29 | 5 | -2.72% | 266,130 |
| 28/24/28 | 5.14 | -2.74% | 183,032 |
| 24/24/24 | 5.285 | +2.82% | 103,081 |
Delayed Quote Nasdaq, May 31, 2024 at 08:49 pm IST
More quotes
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
06/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.99
USD
Average target price
21.2
USD
Spread / Average Target
+324.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.91% | 321M | |
| +10.39% | 114B | |
| +11.02% | 105B | |
| -5.33% | 23.83B | |
| -0.82% | 21.73B | |
| -10.12% | 18.1B | |
| -42.36% | 16.34B | |
| -16.23% | 16.13B | |
| +1.45% | 13.75B | |
| +31.77% | 11.76B |
- Stock Market
- Equities
- MGTX Stock
